- Home
- LEE vs RNXT Comparison
LEE vs RNXT Comparison
Compare LEE & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEE
- RNXT
- Stock Information
- Founded
- LEE 1890
- RNXT 2012
- Country
- LEE United States
- RNXT United States
- Employees
- LEE N/A
- RNXT N/A
- Industry
- LEE Newspapers/Magazines
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- LEE Consumer Discretionary
- RNXT Health Care
- Exchange
- LEE Nasdaq
- RNXT Nasdaq
- Market Cap
- LEE 52.4M
- RNXT 44.6M
- IPO Year
- LEE N/A
- RNXT 2021
- Fundamental
- Price
- LEE $6.17
- RNXT $1.41
- Analyst Decision
- LEE
- RNXT Strong Buy
- Analyst Count
- LEE 0
- RNXT 2
- Target Price
- LEE N/A
- RNXT $7.00
- AVG Volume (30 Days)
- LEE 14.9K
- RNXT 210.6K
- Earning Date
- LEE 05-08-2025
- RNXT 05-15-2025
- Dividend Yield
- LEE N/A
- RNXT N/A
- EPS Growth
- LEE N/A
- RNXT N/A
- EPS
- LEE N/A
- RNXT N/A
- Revenue
- LEE $591,094,000.00
- RNXT $240,000.00
- Revenue This Year
- LEE N/A
- RNXT $3,927.91
- Revenue Next Year
- LEE N/A
- RNXT $219.75
- P/E Ratio
- LEE N/A
- RNXT N/A
- Revenue Growth
- LEE N/A
- RNXT N/A
- 52 Week Low
- LEE $6.15
- RNXT $0.75
- 52 Week High
- LEE $19.63
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- LEE 24.76
- RNXT 78.61
- Support Level
- LEE $6.15
- RNXT $1.17
- Resistance Level
- LEE $6.97
- RNXT $1.30
- Average True Range (ATR)
- LEE 0.28
- RNXT 0.08
- MACD
- LEE -0.06
- RNXT 0.02
- Stochastic Oscillator
- LEE 1.48
- RNXT 100.00
About LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.